Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

4833 Pages (Click to Jump) V  « < 708 709 710 711 712 713 714 > »    
Reply to this topic

post Posted: Sep 20 2018, 10:15 AM
  Quote Post

Posts: 336
Thanks: 773

In Reply To: macgyver's post @ Sep 20 2018, 10:03 AM

Not showed me this page updated 6 hours ago and we are on number two. Whether they are adding or deleting we will find out.

Said 'Thanks' for this post: macgyver  
post Posted: Sep 20 2018, 10:13 AM
  Quote Post

Posts: 336
Thanks: 773

In Reply To: San Diego's post @ Sep 20 2018, 10:09 AM

Thats right. All the NDA mention is now with "Rolling Review"

SCENESSE® awaiting PDUFA date “orphan” porphyria (EPP)

Just noted that new indication in PII on conclusions page.

Photoprotection, DNA repair is coming faster.

Said 'Thanks' for this post: Frogster  Dr Wally  Verharven  PunkassDerm  
San Diego
post Posted: Sep 20 2018, 10:09 AM
  Quote Post

Posts: 149
Thanks: 300

In Reply To: ajshare's post @ Sep 20 2018, 10:05 AM

According to today's Nasdaq Virtual Investor Presentation, they do not appear to have received an "RTF". It states that their current status is "NDA filing, rolling review".

Said 'Thanks' for this post: macgyver  Frogster  Dr Wally  Verharven  
post Posted: Sep 20 2018, 10:05 AM
  Quote Post

Posts: 336
Thanks: 773

In Reply To: macgyver's post @ Sep 20 2018, 10:03 AM

NASDAQ Conference Presentation


post Posted: Sep 20 2018, 10:03 AM
  Quote Post

Posts: 682
Thanks: 664

In Reply To: ajshare's post @ Sep 20 2018, 07:45 AM

This page is unavailable, or needs updating. An old link perhaps?

post Posted: Sep 20 2018, 10:03 AM
  Quote Post

Posts: 620
Thanks: 2217

PW emerges.
Attached File(s)
Attached File  02024364.pdf ( 1.73MB ) Number of downloads: 168


Dr Wolgen is a magician.
His end game for Scenesse will impress, or even amaze.
En route, along with glimmers of truth, there will be distractions, illusions, sleight of hand and misdirection.
Enjoy the ride.

Said 'Thanks' for this post: ajshare

Share Cafe Sentifi Top themes and market attention on:

post Posted: Sep 20 2018, 09:38 AM
  Quote Post

Posts: 823
Thanks: 2152

In Reply To: johnnytech's post @ Sep 20 2018, 07:53 AM

Wow, what a read - FDA concerned by lack of evidence of clear clinical efficacy, apparently requesting additional clinical trials, plus a request for a bioavailability study and yet accepts the NDA 2 weeks later??? Must have been one hell of a response letter (written on $100 bills? jks). Makes what was asked of CUV seem like a non-issue, only that I can't see Team Escargot getting a response in in 2 weeks...

Said 'Thanks' for this post: macgyver  seeva222  
post Posted: Sep 20 2018, 07:53 AM
  Quote Post

Posts: 467
Thanks: 929

In Reply To: ajshare's post @ Sep 20 2018, 07:34 AM

Your example is very interesting. Thanks for researching that. I'm even more confident we have nothing short term to worry about, and I urge we curtail ALL talk about RTFs and Requests For Info, until further press releases are made. The market is watching.

Said 'Thanks' for this post: ajshare  George111  oystercatcher  
post Posted: Sep 20 2018, 07:45 AM
  Quote Post

Posts: 336
Thanks: 773

Is NICE doing a seems like further assessment
Attached thumbnail(s)
Attached Image


Said 'Thanks' for this post: Verharven  johnnytech  Justinian  Frogster  schlitzo  Dr Wally  odi01  Texas T  
post Posted: Sep 20 2018, 07:34 AM
  Quote Post

Posts: 336
Thanks: 773

In Reply To: rabbitrun's post @ Sep 20 2018, 03:50 AM

Don't be too concerned as we will get approval in 2019. Below is a precedent about Alkermes ALKS5461 who had "rolling-review" and it was not an orphan drug.

April 2 2018

Alkermes PLC's hopes to launch a potential blockbuster depression drug later this year have been dashed. The company announced April 2 that it received a refuse-to-file letter from FDA for a new drug application (NDA) for ALKS 5461 for major depressive disorder in patients with an inadequate response to standard antidepressants.

FDA is requesting additional clinical trials before reviewing the application, which suggests a lengthy delay and is particularly problematic for Alkermes given that several other drug developers are circling in on the treatment-resistant depression market.

The refuse-to-file (RTF) letter surprised some investors mainly because management has sounded confident about FDA acceptance and approval later this year, though some investors had remained skeptical because of the data package. During the company's fourth quarter call in February, CEO Richard Pops talked about 2018 as being a year of investment to lay the foundation for growth ahead of the launch of ALKS 5461. (Also see "Late-Stage CNS Drugs Key For Alkermes, But Early-Stage IL-2 Agonist Fascinates" - Scrip, 28 Feb, 2018.)

The company's stock opened 19% lower April 2 on the news at $46.75, and closed down nearly 33% at $45.23. Investors will not be reassured by the fact Pops sounded so surprised about the turn of events during a same-day conference call.

"We have had many interactions with FDA over many years, culminating in a pre-NDA meeting last summer, which led to the commencement of our rolling submission," he said. "While we expected there to be questions during the review process, in none of these interactions did FDA raise concerns which would lead us to expect an RTF."

Alkermes initiated the rolling NDA submission in August 2017, a pathway open because the drug had a fast track designation from FDA, which is intended to help facilitate a faster review of drugs that treat serious conditions or address unmet medical needs. In that way, the letter is unexpected because Alkermes had the opportunity to meet with FDA and agree on the content and timing of the NDA submission.

At the same time, some investors and analysts had remained skeptical that FDA would approve the NDA based on the results of a single Phase III trial. The regulatory approach was considered risky since one trial, FORWARD-5, was positive, but two prior Phase III trials had failed. (Also see "Will Alkermes Data Package Support ALKS 5461 Approval?" - Pink Sheet, 23 Oct, 2016.)

The package included data from four randomized placebo-controlled studies, including Phase II studies, with over 1,500 patients. Another Phase III trial is ongoing.

As Barclays analyst Douglas Tsao put it in a same-day research note, "While we didn't think approval of ALKS 5461 was a certainty, we're surprised that the FDA refused to accept the NDA to review based on a lack of sufficient evidence considering Alkermes' management's confidence in recent months."

More Clinical Studies Needed
The letter cites concerns from FDA about insufficient evidence of overall effectiveness, which doesn't bode well for a quick turnaround of the NDA. A substantial delay could put Alkermes at a competitive disadvantage, given that several rival drugs are advancing through late-stage development in depression, including Johnson & Johnson's esketamine for treatment-resistant depression and SAGE Therapeutics Inc.' brexanolone for postpartum depression. (Also see "How 2018 Will Affect The Depression Market" - Scrip, 7 Feb, 2018.)

Evercore ISI analyst Umer Raffat highlighted the competitive dynamics in an email to investors. "This FDA delay compresses the timelines further amidst several competitor programs making meaningful progress in the depression space," he said. "As a result, we are lowering our peak sales potential (and probability of success) to $800m from $1.2bn."

FDA is requesting additional clinical trials be completed for ALKS 5461 prior to resubmission. The agency has also requested a bioavailability study be conducted to generate additional bridging data between ALKS 5461 and the reference drug buprenorphine.

"This is surprising and troubling to us," Pops said, since the results of the data had been previously shared with FDA in two separate meetings and presented at a major medical meeting.

"FDA did not express their view that the evidence of effectiveness was insufficient to support a full review of the NDA," he said. "We obviously disagree with FDA's conclusions, and we expect them to only render final judgement after a complete review of the NDA."

Alkermes plans to appeal FDA's decision. Pops said the company will immediately request a Type A meeting with FDA to determine the next steps. The company said it may also need to revise its 2018 financial guidance.

The company forecasted in February that revenues would grow to $975m to $1.015bn this year, driven by currently marketed drugsVivitrolandAristada, but Alkermes also expected a substantial increase in SG&A expenses driven by commercial investment in ALKS 5461.

ALKS 5461 is a novel oral medicine that acts as an opioid system modulator. It is positioned as an add-on therapy for patients with MDD who don't respond adequately to current therapies. It is a fixed-dose combination of the partial mu-opioid receptor agonist and kappa-opioid receptor antagonist buprenorphine and a mu-opioid receptor antagonist samidorphan.

Two weeks later NDA was accepted by FDA

Said 'Thanks' for this post: johnnytech  Justinian  Dr Wally  

4833 Pages (Click to Jump) V  « < 708 709 710 711 712 713 714 > » 

Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.